Cancer chemotherapy and radiation induced emesis (CRIE): Current and future therapeutic approaches

Indian Journal of Pharmacology

Volumn 32, Issue 5, 2000, Pages 256-268

  Abraham, A ^a   Sridhar, N ^a   Veeranjaneyulu, A ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT3 antagonists; Chemotherapy and radiation; Emesis; NK1 antagonists

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 5 [[3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYL 1 PIPERIDINYL]METHYL] 1,2 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CANNABINOID DERIVATIVE; CARMUSTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GR 2015171; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SCREENING; FERRET; HUMAN; NAUSEA; NONHUMAN; REVIEW; VOMITING;

EID: 0033768265     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Physiology and pharmacology of vomiting
2. The physiology and pharmacology of emesis
3. Nausea and vomiting as major complications of cancer chemotherapy
4. Physiology of chemotherapy induced emesis and anti-emetic therapy: Predictive models for evaluation of new compounds
5. Digestive tract motor correlates of vomiting and nausea
6. Pharyngeal, oesophageal and proximal gastric responses associated with vomiting
7. Respiratory muscle control during vomiting
8. The mechanism of emesis induced by anti-cancer therapies
9. A new concept of organization of the central emetic mechanism: Recent studies on the sites of action of apomorphine, copper sulphate and cardiac glycosides
10. The abdominal innervation and the emetic reflex; pathways, pharmacology and plasticity
11. Morphology of emetic chemoreceptor trigger zone in cat medulla oblangata
12. Neural mechanisms of emesis
13. Neuropharmacology of chemotherapy induced emesis
14. Cisplatin induced vomiting eliminated by ablation of the area prostrema in cats
15. Role of the area postrema in vomiting and related functions
16. Pharmacological agents affecting emesis: A review (Pt I)
17. Prospective study of the clinical symptoms of therapeutic whole body irradiation
18. Prospects for management of gastrointestinal injury associated with the acute radiation syndrome
19. Optimum management of nausea and vomiting in cancer chemotherapy
20. Cost - reducing algorithms for antineoplastic drug - induced nausea and vomiting
21. Incidence, course and severity of delayed nausea and vomiting following the administration of high dose Cisplatin
22. The course of nausea and vomiting after high dose cyclophosphamide
23. Urinary serotonin metabolite excretion during cisplatin chemotherapy
24. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery
25. Control of chemotherapy induced emesis
26. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients
27. Cancer therapy, vomiting, and antiemetics
28. Neuropharmacology of emesis induced by anti-cancer therapy
29. Chemotherapeutic agents do not interact with neurotransmitter receptors
30. 1, muscarine cholinergic and alpha 1 adrenergic receptors
31. Cytotoxic - therapy - induced vomiting is mediated via enkephalin pathways
32. The role of the abdominal visceral innervation and 5-hydroxytryptamine M receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret
33. The gastrointestinal tract in chemotherapy induced emesis: A final common pathway
34. Physiology of chemotherapy - induced emesis and antiemetic therapy
35. Effects of inhibition of serotonin synthesis on 5-hydroxy indole acetic acid excretion, in healthy subjects
36. Antagonism by parachloro-phenyl-alanine of cisplatin induced emesis
37. Efficacy of ondansetron (GR38032F) and the role of cisplatin - induced nausea and vomiting
38. VIIIth International Union of Pharmacology classification of receptors for 5- Hydroxy tryptamine (serotonin)
39. Therapeutic potentials of 5-HT receptor modulators
40. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs
41. 3 receptor antagonists injected into the area postrema inhibits cisplatin induced emesis in the ferret
42. 3 antagonists in the ferret
43. 3 receptor antagonist with anti-emetic properties
44. The role of serotonin as a mediator of emesis induced by different stimuli
45. Plasma chromogranin a marks emesis and serotonin release associated with dicarbazine and nitrogen mustard but not with cyclophosphamide
46. 4 receptors in zacopride and copper sulphate induced vomiting in the ferret
47. 4 receptors in copper sulphate induced vomiting in dogs
48. 5-HT(1A) receptor agonists as anti-emetics
49. Tachykinin and tachykinin receptor antagonits
50. Mammalian tachykinin receptors
51. Autoradiographic localization of receptors in peripheral tissues
52. Distribution of substance P like immuno-reactive neurons and terminals throughout the nucleus of the solitary tract in the human brain stem
53. 1 receptor
54. 5-Hydroxytryptamine containing enterochromaffin cells: Storage site of substance P
55. The tachykinin receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret
56. 1 receptor antagonist act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets
57. Elevation of plasma anti-diuretic hormone (ADH) associated with chemotherapy induced emesis in man
58. Arginine vasopressin - A mediator of chemotherapy induced emesis?
59. Mechanisms by which cancer chemotherapeutic drugs induce emesis
60. Human distribution and release of a putative new gut hormone peptide YY
61. Identification and characterization of the emetic effects of Peptide YY
62. Plasma levels of peptide YY correlates with cisplatin induced emesis in dogs
63. The assessment of nausea and vomiting: Past problems, current issues, and suggestions for further research
64. Visual analogue scales: Measurement of subjective phenomena
65. Nausea, vomiting and retching: The management of the symptom experience
66. 3 receptor antagonists
67. The concept of selectivity in 5-HT research
68. Animal models in the study of vomiting
69. Emesis induced by cisplatin in the ferret as a model for the detection of antiemetic drugs
70. 3 receptors: Pharmacologic and therapeutic aspects
71. 3 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting
72. Enantioselective inhibition of apomorphine induced emesis in the ferret by neurokinin 1 receptor antagonist CP99,994
73. 1 receptor antagonist, CP-99,994 in ferrets
74. Resinferotoxin, an ultrapotent capsacin analogue, has antiemetic properties in the ferret
75. Neurokinin antagonists as potential therapies for inflammation and rheumatoid arthritis
76. 1 receptor antagonist GR203040
77. Neurokinin receptor antagonist
78. Patterns of nausea and vomiting in children: Nursing assessment and intervention
79. Contributions of benzo-diazepines to cancer therapy
80. Plasma concentrations following oral and sublingual administration of lorazepam
81. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam
82. Sublingual lorazepam: A better premedication?
83. Is sublingual lorazepam beneficial for patients on emetogenic chemotherapy? A double-blind randomized and cross-over study
84. Oral lorazepam to improve tolerance of cytotoxic therapy
85. 3 receptor antagonists injected into the area postrema inhibits cisplatin induced emesis in the ferret
86. 3 antagonists in the ferret
87. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
88. The concept of selectivity in 5-HT research
89. 3 receptors: Pharmacologic and therapeutic aspects
90. 3 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting
91. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting
92. Oral treatment with ondansetron in an outpatient setting
93. Enantioselective inhibition of apomorphine induced emesis in the ferret by neurokinin 1 receptor antagonist CP-99,994
94. 1 receptor antagonist, CP-99,994 in ferrets
95. Resinferotoxin, an ultrapotent capsacin analogue, has antiemetic properties in the ferret
96. 1 antagonist GR203040 inhibits cyclophosphamide-induced damage in the ferret and rat bladder
97. Neurokinin antagonists as potential therapies for inflammation and rheumatoid arthritis
98. 1 receptor antagonist GR203040
99. 3 receptor antagonist in the treatment of fractionated radiotherapy induced nausea and emesis
100. Neurokinin receptor antagonist